Ovarian Cancer | Specialty

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Leave No One Behind: Optimizing Targeted Therapies in Ovarian Cancer

July 1st 2019

The development of targeted therapies, including bevacizumab (Avastin) and 3 PARP inhibitors, is changing treatment paradigms for women with epithelial ovarian cancer.

Dr. Penson on Olaparib Monotherapy Vs Chemo in Ovarian Cancer

June 20th 2019

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital, compares olaparib (Lynparza) monotherapy with chemotherapy for patients with relapsed germline BRCA-mutated (gBRCAm) platinum-sensitive ovarian cancer.

Frontline Maintenance Olaparib Approved in Europe for Ovarian Cancer

June 18th 2019

The European Commission has approved olaparib as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Moving Molecular Testing to the Frontlines of Ovarian Cancer

June 10th 2019

Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.

Sorting Through Unanswered Questions in Ovarian Cancer

June 10th 2019

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

SOLO-1 Olaparib Trial Fosters Novel Applications of Frontline Maintenance in Ovarian Cancer

June 7th 2019

Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.

Olaparib Extends PFS, Hits High Response in Confirmatory BRCA+ Ovarian Cancer Trial

June 4th 2019

The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.

Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer

June 4th 2019

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

ACA Improved Ovarian Cancer Diagnosis and Time to Treatment

June 2nd 2019

Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019

ASCO 2019: Dr. Monk on Promising Abstracts in Gynecologic Malignancies

June 2nd 2019

ASCO 2019: Dr. Horn Highlights Progress in Lung Cancer

June 2nd 2019

ASCO 2019: Dr. Shah Covers Potentially Practice-Changing GI Cancer Studies

June 2nd 2019

ASCO 2019: Dr. Tagawa Highlights Key Prostate Cancer Data

June 2nd 2019

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma Studies

June 2nd 2019

OncLive News Network On Location: In Chicago Tuesday, June 4

June 2nd 2019

OncLive News Network On Location: In Chicago Monday, June 3

June 2nd 2019